Quality. Independence. Impact.

Home | Contact Us | Media Resources

Saturday November 7, 2009

Welcome   |   Register   |   Log in

Past Event

AN ENGELBERG CENTER FOR HEALTH CARE REFORM AND HAMILTON PROJECT EVENT

Implementing Comparative Effectiveness Research: Priorities, Methods and Impact

Health Care


Event Summary

The American Recovery and Reinvestment Act of 2009 invested $1.1 billion in federal initiatives to begin the important and necessary work of comparative effectiveness research (CER), a key building block in health care reform. However, whether CER can fulfill expectations of better quality, outcomes and value in health care will depend on how it is implemented.

Event Information

When

Tuesday, June 09, 2009
8:30 AM to 12:45 PM

Where

Falk Auditorium
The Brookings Institution
1775 Massachusetts Ave., NW
Washington, DC
Map

Contact: Brookings Office of Communications

E-mail: events@brookings.edu

Phone: 202.797.6105

RELATED CONTENT

Save to My PortfolioConference on Clinical Cancer Research

Monday, September 14, 2009
8:30 AM to 4:30 PM
Washington, DC

Save to My PortfolioA Macropolicy View of Comparative Effectiveness Research

Mark B. McClellan, U.S. Chamber of Commerce, January 15, 2009

Save to My PortfolioFour Important Steps Toward 21st Century Care for Patients with Cancer

Mark B. McClellan, The Oncologist, April 13, 2009

More Related Content »

A forum hosted by the Engelberg Center for Health Care Reform and The Hamilton Project addressed many of the key questions surrounding CER and featured remarks from Sen. Max Baucus (D-Mont.) and Office of Management and Budget Director Peter Orszag. Three discussion papers released at the event focus on how research questions should be prioritized, what methods and data infrastructure are needed for CER, and how CER findings can be used to improve clinical and health policy decisions. A series of distinguished panels discussed the papers' findings.

Participants took questions after each panel.

Watch the archived webcast »
 
Download discussion papers »

Transcript

MARK MCCLELLAN: Comparative Effectiveness Research has vaulted to the front lines of the Health Care Reform debate. As you'll hear from some of our upcoming speakers, it could even be a game-changer, a key part of bending the health care cost curve, and comparative effectiveness research is moving forward. The American Recovery and Reinvestment Act of this year, the economic stimulus legislation invested $1.1 billion in federal initiatives to conduct comparative effectiveness research and expand current activities. This includes an effort to coordinate new and existing efforts in comparative effectiveness research.

The legislation created a new Federal Coordinating Council, which has begun its work. The Institute of Medicine will produce its recommendations under the law for national priorities for national comparative effectiveness research efforts by the end of this month. But fulfilling that promise of comparative effectiveness research for better quality, better outcomes, and value in health care will require answering some important questions that have not yet been tackled. There are some differences in views about whether comparative effectiveness research can have a substantial impact on the health care cost growth curve, and there are some further concerns about whether that happening is a good thing, whether such restrictions on cost growth would be a good thing.

As we'll talk about today, what kind of impact can come from comparative effectiveness research may come down, not just to whether we spend the money but how it's done. Such questions include what research issues should be prioritized, what methods are appropriate for comparative effectiveness research, and where will the data come from, and how can comparative effectiveness research findings be used to maximize the impact on clinical and health policy decisions.

Participants

Welcome

Mark B. McClellan

Director, Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies

The Future of Comparative Effectiveness Research in the United States

The Honorable Max Baucus (D-Mont.)

United States Senate

Introductory Remarks

Robert E. Rubin

Former Secretary, U.S. Department of the Treasury
Advisory Council, The Hamilton Project

Getting Our Money's Worth from Patient-Centered Health Research

Peter Orszag

Director, Office of Management and Budget

Comparative Effectiveness Research: What It Is, What It's Not and Why We Need More

Moderator: Mark B. McClellan

Director, Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies

Kathleen Buto

Vice President, Health Policy, Government Affairs, Johnson & Johnson

Carolyn Clancy

Director, Agency for Healthcare Research and Quality

David Lansky

President and CEO, Pacific Business Group on Health

John Rother

Executive Vice President of Policy and Strategy, AARP

Setting Priorities for Comparative Effectiveness Research (Discussion Paper 1)

Presenter: Alan Garber

Director, Center for Primary Care and Outcomes Research, Stanford School of Medicine

Presenter: David Meltzer

Associate Professor, University of Chicago School of Medicine

Mark Miller

Director, MedPAC

Elizabeth Nabel

Director, National Heart, Lung, and Blood Institute

Harold Sox

Past President, American College of Physicians

Strategies to Improve Comparative Effectiveness Research Methods and Data Infrastructure (Discussion Paper 2)

Presenter: Sean Tunis

Director, Center for Medical Technology Policy

Robert Califf

Vice Chancellor for Clinical Research and Professor of Medicine, Duke University School of Medicine

Joshua Ofman

Vice President of Global Coverage & Reimbursement and Global Health Economics, Amgen

Sebastian Schneeweiss

Assistant Professor, Harvard Medical School

Ellen Sigal

Chair and Founder, Friends of Cancer Research

From Better Evidence to Better Care: Using Comparative Effectiveness Research to Guide Practice and Policy (Discussion Paper 3)

Presenter: Steven Pearson

Director, Institute for Clinical and Economic Review

Steven Findlay

Senior Health Policy Analyst, Consumers Union

Scott Gottlieb

Resident Fellow, American Enterprise Institute for Public Policy Research

Marc Berger

Vice President, Global Health Outcomes, Eli Lilly & Co.

Sam Nussbaum

Executive VP and Chief Medical Officer, WellPoint

Closing Remarks

Mark B. McClellan

Director, Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies


Advanced Search | Tips

My Portfolio

My New Content

View suggested content based on items you have saved to your Portfolio.
Log in or register now

Related Topics

View All Topics »